Deal-Making

Amgen thanks BMS-Celgene merger in creating China opportunity

The opportunistic nature of its partnership with BeiGene threw Amgen into the ever-increasingly attractive China market, management said at JP Morgan. At the JP Morgan Healthcare Conference in San Francisco this week, Amgen reflected on its 2019 M&A activity and counted itself as a beneficiary of rival Big Biopharma firm Bristol-Myers Squibb’s (BMS)  Celgene acquisition for $74 billion (€66 billion). From a product perspective, regulatory divestiture demands led Amgen to pick up the global rights to psoriasis drug Otezla (apremilast)…

Waters adding automation lab tech by buying Andrew Alliance

Waters Corporation will add an automated software system and robotics technology through the acquisition of Swiss biotech firm Andrew Alliance. Life sciences chromatography and measurement company Waters Corporation has not divulged the financial details of the deal, but a company spokesman said it significantly bolsters its lab tech portfolio through the addition of automated technologies. “Andrew Alliance’s cloud-native software platform and user interface dramatically improves the use of automation technology, enabling more scientists to realize the advantages of repeatability and…

Yposkesi to make Genethon and Sarepta’s DMD gene therapy

Genethon and Sarepta have contracted Yposkesi to make AAV material for a Duchenne muscular dystrophy (DMD) gene therapy they are developing. The therapy in question is called GNT0004. It consists of an AAV-type viral vector and a shortened version of the dystrophin gene (microdystrophin). According to preclinical data published in the journal Nature the therapy is able to produce significant restoration of muscle function with stabilization of clinical symptoms. Under the new manufacturing deal Yposkesi will produce clinical and large-scale…

In with the new… Deal completions from Catalent, CRL and Janssen

It’s a happy new year for Catalent, Charles River and Janssen, which have closed their respective acquisitions of a fill/finish facility, cell therapy services firm and an investigative mAb. In December, Roche completed its $4.3 billion (€3.9 billion) acquisition of commercial gene therapy firm Spark Therapeutics, 10 months after the deal was announced. But the Swiss Biopharma is not the only firm to begin 2020 with new assets, as several others in the life science space have announced the completion…

Getinge pays $89m for Applikon to boost life sciences biz

Getinge has bought Applikon Biotechnology to expand its life sciences technologies business. Sweden’s Getinge announced it would pay SEK 840 million ($89 million) for Applikon last month. It said the Dutch bioreactor firm’s technology portfolio would bolster its biopharma segment. It cited Applikon’s range of systems for the research and production of vaccines and antibodies as well as those for the production of enzymes and bio-plastics as the main motivation. “Applikon Biotechnology has a strong portfolio of world class bioreactor solutions…

Twist to biopharma with Pandion antibody optimization expansion

Twist Bioscience will leverage its antibody optimization platform to help develop further autoimmune and inflammatory candidates for Pandion Therapeutics. The two firms have completed an initial project using Twist’s antibody optimization platform based on DNA sequencing technology and will now collaborate on further antibodies for autoimmune regulation. Twist Biopharma – a division of California-based Twist Bioscience – CEO Emily Leproust said the deal with Pandion “is an excellent example of how our antibody optimization solution can change the discovery and…

Lonza teams with 3D bioprinting firm Allevi

Lonza has partnered with 3D bioprinting materials firm Allevi citing growing biopharma demand for bespoke organs for drug discovery research. The collaboration – terms of which were not disclosed – will see the Swiss contract development and manufacturing organization (CDMO) combine its primary cells and culture media with Philidelphia-based Allevi’s range of bioprinter and bioink production technologies. The idea is to cater for biopharma developers looking to manufacture organs and tissues for drug discovery. Lonza said it collaborates with selected…

Biotech VC down 20% in US as policies drive away foreign investors, BIO

Reforms to a US national security regulation are putting off foreign investors and driving down VC investment in the biotech space by as much as 20 percent, says BIO’s David Thomas. In August 2018, Congress passed the Foreign Investment Risk Review Modernization Act (FIRRMA) as part of the Fiscal 2019 National Defense Authorization Act. The Act broadened the scope and oversight of the Committee on Foreign Investment in the United States (CFIUS) to include the review of foreign investments in companies…

The 12 trends of Christmas: A look back at 2019

CAR-T partnerships, Biopharma megamergers, biotech funding, and an eye on China. Bioprocess Insider presents the biggest stories of the year… through song! T’was the days before Christmas, And all through the dept. Not a story was breaking and journalists wept. So why not look back at the news of the year, The editor suggested over a beer… In the past twelve months Bioprocess Insider brought to you (To the tune of traditional Christmas song ‘The Twelve Days of Christmas’): A…

Novartis inks 5 years vector supply extension with Oxford Biomedica

Oxford Biomedica will keep supplying Novartis with the vectors needed to make Kymriah and other CAR-T products under a five-year deal extension. The new agreement will see Oxford Biomedica receive $75 million for manufacturing, undisclosed process development payments, a facility reservation fee as well as previously agreed royalties on chimeric antigen receptor (CAR-T) product sales. The extension deal also requires the firm ensure at least two manufacturing facilities are capable of commercial supply. Oxford Biomedica will make the vectors at…